Directory of registries

Terminated clinical registry of kidney cancer patients who were treated with bevacizumab (Avastin®), everolimus (Afinitor®), pazopanib (Votrient®), sorafenib (Nexavar®), sunitinib (Sutent®) and/or temsirolimus (Torisel®).

start of the project: January 2007

end of the project: July 2018

The RenIS registry (Renal carcinoma Information System) was a non-interventional post-authorisation trial focused on the collection of epidemiological and clinical data on kidney cancer patients treated with biological therapies in the Czech Republic. The registry monitored kidney cancer treatment with bevacizumab (Avastin®), everolimus (Afinitor®), pazopanib (Votrient®), sorafenib (Nexavar®), sunitinib (Sutent®) and temsirolimus (Torisel®). The project had been initiated in June 2007 at the Institute of Biostatistics and Analyses of the Masaryk University (IBA MU) and continued at the Institute of Biostatistics and Analyses Ltd (IBA Ltd), a university company.

The obtained data allowed researchers to monitor the epidemiological characteristics of kidney cancer patients as well as applied treatment regimens, to analyse patients’ response to treatment, to model the influence of risk factors on patients’ survival and a to perform detailed analyses of recorded adverse effects.

Although the applied data collection system was primarily focused on treatment of advanced disease and of disseminated relapses, it also involved all significant data related to the primary tumour. The universal and generally valid data structure of the registry allowed researchers to follow any treatment pattern in a logical context of disease progression, while taking into account the influence of factors which significantly affect treatment results.

The project was open to cooperation with all Comprehensive Cancer Centres in the Czech Republic. The system was based on an on-line technology which enabled a high-quality central management and administration of data from individual centres while respecting their rights as unique owners of their clinical data. The flexibility and openness of the on-line system for data collection and assessment allowed further extensions to specific items.

Primary objectives of the project:

  • monitoring the overall number of kidney cancer patients in the Czech Republic treated with sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab a pazopanib,
  • assessment of safety of the above-mentioned drugs,
  • assessment of effectiveness of the above-mentioned drugs and of applied treatment regimens.

Secondary objectives of the project:

  • analysis of patients’ survival in relation to monitored clinical factors,
  • analysis of patient cohort treated with biological therapies in relation to Czech reference population data.

Other important information:

  • Expert guarantor: Katarína Petráková, MD, PhD (Czech Society for Oncology)
  • Partners: 20 specialized centres in the Czech Republic (you can find more detailed information on the website of the Renis project)
  • Brief overview of results: you can find more detailed information on the website of the RENIS project
RENIS: clinical registry of patients with malignant neoplasm of kidney